Bayer: reduces net loss to 672 million in the third quarter and revises its guidance upwards
(Il Sole 24 Ore Radiocor) - The German chemical and pharmaceutical multinational Bayer ended the third quarter by reducing its losses and has revised its forecasts for 2026 upwards. The net loss for the quarter stood at 672 million, an improvement on the 963 million recorded in the third quarter of 2025. During the period in question, turnover grew by 4.1% to 10.05 billion; EBIT remained in negative territory but at 110 million, compared with -543 million in the third quarter of 2025. EBITDA, excluding extraordinary items, rose to 1.615 billion euros (up 6.9 per cent)
“The results achieved since the start of the year show that our strategy is working and give us the confidence to raise our annual targets for adjusted EBITDA, liquidity and debt,” said Judith Hartmann, Bayer’s chief financial officer.
"Over the first nine months, Bayer is on track operationally with the targets set for the full financial year and also aims to capitalise on improving trends as the year draws to a close. “We have reached a turning point in the growth trajectory of the Pharmaceuticals division and are beginning to see the light at the end of the tunnel,” said Chief Executive Bill Anderson.
red-fil
